Compare Illumina, Inc. (ILMN) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Xpeng Inc - ADR — how do they compare? Illumina, Inc. trades at $180.13 (market cap $27.94B), while Xpeng Inc - ADR trades at $13.22 (market cap $12.96B). The key difference: Illumina, Inc. is far larger — about 2.2× Xpeng Inc - ADR's market cap, and Illumina, Inc. is trading nearer its 52-week high, Xpeng Inc - ADR nearer its low. Which is the better fit depends on your goals.
| ILMN | XPEV | |
|---|---|---|
Market Cap | $27.94B | $12.96B |
Sector | Health | Consumer Cyclical |
52-Week High | $194.33 | $28.07 |
52-Week Low | $91.00 | $12.09 |
Enterprise Value | $29.33B | $15.07B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
XPEV stock trades at $13.22, down 2.33% on the day, with a neutral technical outlook. The company reported revenue of $76.72 billion in 2025, but net losses persist, though the margin improved to -1.49%. Recent news highlights overseas expansion with the L03 SUV launch in Munich and progress in autonomous driving technology. Analyst consensus is bullish with a $17.00 price target, but cash flow volatility and competitive pressures remain concerns.
The outlook for XPEV hinges on execution of global expansion and new model launches to drive profitability. Investment opportunity lies in market share gains and technology leadership in EVs and AI, but risks include intense competition, reliance on Chinese market dynamics, and ongoing cash burn. The stock offers growth potential if the company can sustain revenue growth and narrow losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
